抗RANKL抗体薬の薬物動態～デノスマブ［１回/６カ月（皮下注）］～

Pharmacokinetics and usage of drug for treatment of osteoporosis. Pharmacokinetics of anti-RANKL antibody drugs：Denosumab.

　分子量が10万を超える糖タンパク質である抗体医薬品は，ここ数年で急激にその承認数が増えているものの，従来の低分子薬とはその作用機序や薬物動態の点で，従来の低分子医薬品とは大きく異なり，その体内動態も従来と異なる特徴を持つことが予想される。本稿では，始めに一般的な抗体医薬品の特徴について体内動態を中心に述べた後，ヒト型抗RANKLモノクローナル抗体であるデノスマブの薬物体内動態の特徴とスペシャルポピュレーションにおける体内動態の変化についての検討を概説した。

　Antibody drug is a kind of glycoprotein which molecular weight is over one hundred thousand. The number of pharmaceutical approval of antibody drug has been increasing in recent years. In terms of a working mechanism and pharmacokinetics, antibody drug is markedly different from existing low molecular weight drugs. In prospect, about body kinetics is the same. This paper describes general features of antibody drug mainly about internal kinetics in the first half. In the last half, body kinetics of human anti-RANKL monoclonal antibody called Denosumab and body kinetics changes in special population are outlined.